TB-500 dosing in the research literature

TB-500 Dosing in the Research Literature

TB-500 dosing in the research literature is animal-model and Phase-1 data — not a human protocol, and almost entirely for full-length thymosin beta-4 rather than the Ac-LKKTETQ fragment ^[15][7]. This section describes what was administered to which species at which dose by which route. It does not recommend a dose for any person.

Rodent efficacy studies dose across a wide range. Cardiac and neurological models used roughly 6–12 mg/kg; the embolic-stroke dose-response study used 2, 12 and 18 mg/kg intraperitoneally, with a modeled optimal near 3.75 mg/kg and no benefit at the highest dose ^[10]. The mdx muscular-dystrophy study used 150 µg twice weekly intraperitoneally for 6 months ^[15]. At the other end of the scale, picogram-to-nanogram amounts are bioactive in vitro — about 10 pg was active in keratinocyte migration assays, and nanomolar thymosin beta-4 stimulates hair-follicle stem cells ^[8][1].

Human dosing data, and its limits

The only controlled human dosing data are for the parent protein. In the randomized, placebo-controlled Phase 1 study, synthetic thymosin beta-4 was given intravenously to 40 healthy volunteers as a single dose then daily for 14 days at 42, 140, 420 or 1260 mg; it was well tolerated to 1260 mg with no dose-limiting toxicities or serious adverse events, and pharmacokinetics were dose-proportional ^[13]. There is no equivalent controlled human dosing study for the TB-500 7-mer ^[15]. Community "loading then maintenance" protocols circulating in athletic and peptide-research settings are not derived from controlled human trials and have no published clinical validation ^[15].

The potency range: from picograms to milligrams

One feature of the thymosin beta-4 literature complicates any simple notion of a "dose": the molecule is active across an enormous concentration span. At the low end, as little as 10 pg stimulated keratinocyte migration 2–3-fold in assays, and nanomolar concentrations activated hair-follicle stem cells ^[8][1]. At the high end, whole-animal models used milligram-per-kilogram intraperitoneal doses, and the human Phase 1 went to 1260 mg intravenously ^[10][13].

That span is a property of the parent protein in controlled settings, not a menu. It tells you the molecule is bioactive at trace levels in vitro and was tolerated at gram-scale exposure in one IV human study ^[13] — it does not tell you what a research-use quantity does in a person, because that study does not exist for the 7-mer ^[15]. The honest reading is that potency is broad and well documented in cells and animals, and undetermined for the fragment in humans.

What is the half-life of TB-500?

The TB-500 half-life is, in honest terms, uncharacterized: no validated human pharmacokinetic half-life exists for the TB-500 heptapeptide ^[13]. In the IV full-length thymosin beta-4 Phase 1 study, half-life increased with dose (dose-proportional PK) ^[13]. Anti-doping LC-MS work characterizes TB-500 and its metabolites in equine plasma and urine for detection purposes, not for human PK ^[13]. The honest statement is that the fragment's human half-life is uncharacterized, and any circulating "twice-weekly" rationale is a community convention, not a pharmacokinetic finding ^[15].

Routes studied

Intraperitoneal injection predominates in rodent efficacy studies ^[10][7]. Intravenous administration was used in the human Phase 1 of full-length thymosin beta-4 and in some cardiac models ^[13]. Topical and ophthalmic routes were used in corneal and dermal wound work and dry-eye RCTs for the clinical-grade formulation RGN-259 ^[7]. Subcutaneous and intramuscular routes appear in community research use but not in controlled human efficacy trials ^[7].

Why species and route matter when reading these numbers

A dose figure is meaningless without its species and route, which is why this digest never strips them. The rodent intraperitoneal doses (2–18 mg/kg) and the human intravenous doses (42–1260 mg) are not convertible into each other by simple arithmetic, and neither converts into a subcutaneous research-use figure for a person ^[10][13]. Allometric scaling, the difference between the protein and the fragment, and the absence of human PK for the 7-mer all sit between an animal number and any human meaning ^[13][7].

The non-monotonic stroke result is the cleanest warning against extrapolating upward. In that study, 2 and 12 mg/kg helped and 18 mg/kg did not — more was not better, and the modeled optimum sat near 3.75 mg/kg ^[10]. Whatever the mechanism behind that ceiling, it argues directly against the community premise that a larger "loading" exposure is safer or more effective ^[15]. The literature supports describing what was studied; it does not support a person's protocol.

Handling and stability

Research-grade TB-500 is supplied as a lyophilized (freeze-dried) powder, reconstituted in bacteriostatic or sterile water and kept refrigerated. As a short acetylated peptide it is more chemically robust than the full-length protein, but it is still subject to proteolysis and freeze-thaw degradation. Identity and purity of research-grade material — including whether the contents are the 7-mer or full-length thymosin beta-4 — are recurring concerns, and they complicate the interpretation of any reported result.